Humira is a brand-name drug prescribed to treat rheumatoid arthritis, psoriatic arthritis, and more. It can remain unrefrigerated for up to 14 days, as long as the temperature doesn’t go above 77°F ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The judge in former President Donald J. Trump’s Manhattan criminal trial, Juan M. Merchan, issued instructions to jurors on Wednesday that serve as a guide to applying the law in deliberations. A PDF ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Evernorth Health Services, a subsidiary of Cigna, will have a Humira biosimilar available for $0 out-of-pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The high- ...

Please provide your email address to receive an email when new articles are posted on . AbbVie reported a worldwide net revenue of $12.31 billion and a 0.7% increase in its first quarter. Global net ...

Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company announced Thursday. Accredo is the specialty pharmacy segment within Evernorth ...

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved ...